These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 1992325)
41. The role of immunoglobulin in bone marrow transplantation. Saral R Transplant Proc; 1991 Aug; 23(4):2128-32. PubMed ID: 1871829 [TBL] [Abstract][Full Text] [Related]
42. Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation. Champlin RE; Mitsuyasu RT; Gale RP Prog Clin Biol Res; 1985; 193():315-25. PubMed ID: 3911215 [No Abstract] [Full Text] [Related]
43. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
44. [Monitoring lymphocyte activity in the peripheral blood of patients after bone marrow transplantation]. Hrabánek J; Lukásová M; Chudomel V; Smetana K Cas Lek Cesk; 1994 Jan; 133(3):80-2. PubMed ID: 8137377 [TBL] [Abstract][Full Text] [Related]
45. Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation. Fehir KM; Decker WA; Samo T; Young JB; Lederer E; Lawrence EC Transplant Proc; 1989 Feb; 21(1 Pt 3):3107-9. PubMed ID: 2539691 [No Abstract] [Full Text] [Related]
52. Stability of normal human IgG in saline and glycine solutions. Patterson MR; Smith JK Vox Sang; 1974; 26(6):560-4. PubMed ID: 4854376 [No Abstract] [Full Text] [Related]
53. Commentary: Applying a causal road map in settings with time-dependent confounding. Petersen ML Epidemiology; 2014 Nov; 25(6):898-901. PubMed ID: 25265135 [No Abstract] [Full Text] [Related]
54. Collection and handling of bone marrow suspensions for intravenous use. BOYUM A Scand J Clin Lab Invest; 1962; 14():419-24. PubMed ID: 13872225 [No Abstract] [Full Text] [Related]
55. Noncomparability among IgG products. McCue JP; Johnson AJ Transfusion; 1986; 26(5):489. PubMed ID: 3765049 [No Abstract] [Full Text] [Related]
56. Removal of tumour cells from bone marrow: overview. Bron D; Stryckmans P Eur J Cancer Clin Oncol; 1989 Feb; 25(2):163-6. PubMed ID: 2649373 [No Abstract] [Full Text] [Related]
57. Comment on undegraded human 7S-immunoglobulin for intravenous use. Wadsworth C Vox Sang; 1976 Nov; 31(5):394-400. PubMed ID: 1007163 [No Abstract] [Full Text] [Related]
58. Factors affecting the production of intravenous immunoglobulin. Matejtschuk P; More J Biochem Soc Trans; 1990 Apr; 18(2):309-10. PubMed ID: 2116339 [No Abstract] [Full Text] [Related]
59. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. Siadak MF; Kopecky K; Sullivan KM Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):53-7. PubMed ID: 8033436 [TBL] [Abstract][Full Text] [Related]
60. Intravenous IgG to prevent graft-versus-host disease after bone marrow transplantation. N Engl J Med; 1991 Feb; 324(9):631-3. PubMed ID: 1992325 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]